ALSP Inc. is a privately held company based in San Diego, California, developing small molecule drugs for treating neurodegenerative diseases, initially focused on Alzheimer's disease and traumatic brain injury (TBI). Our approach is to identify key enzymes in the brain, called neuroproteases, that produce biologically active peptides that are thought to cause the condition. We then use those enzymes as targets for screening compounds that inhibit the neuroproteases and thereby reduce production of the harmful peptides to treat the condition.
Since Drs. Katz, von Euler and Axelrod were awarded the Nobel Prize in Physiology or Medicine in 1970 for their discoveries concerning the humoral transmitters in the nerve terminals and the mechanism for their storage, release and inactivation, the process of studying neurotransmitters and the enzymes that produce them have flourished. By using this well-established process, we have identified a famlly of drugs that is highly effective at reversing the symptoms of Alzheimer's and TBI in animal models of these conditions. We are advancing our lead compound into clinical trials and continuing our search for additional drugs to treat Alzheimer's and other devastating neurodegenerative diseases.